Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): Study protocol for a double-blind randomized placebo-controlled trial

Trials

Volumn 14, Issue 1, 2013, Pages

  Fekadu, Abebaw ^a,b   Mesfin, Miraf ^a   Medhin, Girmay ^c   Alem, Atalay ^a   Teferra, Solomon ^a   Gebre Eyesus, Tsehaysina ^d   Seboxa, Teshale ^c   Assefa, Abraham ^e   Hussein, Jemal ^e   Lemma, Martha T ^f   Borba, Christina ^g   Henderson, David C ^g   Hanlon, Charlotte ^a,b   Shibre, Teshome ^a  

^a ADDIS ABABA UNIVERSITY   (Ethiopia)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ADDIS ABABA UNIVERSITY   (Ethiopia)

^d ST PAUL S HOSPITAL MILLENNIUM MEDICAL COLLEGE   (Ethiopia)

^e All Africa Leprosy Tuberculosis and Rehabilitation Training Centre Addis Ababa   (Ethiopia)

^f BAHIR DAR UNIVERSITY   (Ethiopia)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Clinical trial; Ethiopia; Intervention; Minocycline; Schizophrenia

Indexed keywords

MINOCYCLINE; OLANZAPINE; PLACEBO; RISPERIDONE;

ADJUVANT THERAPY; ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ETHIOPIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; POSITIVE SYNDROME; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOPHRENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MINOCYCLINE; NEURODEGENERATIVE DISEASES; SAMPLE SIZE; SCHIZOPHRENIA;

EID: 84888247485     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-14-406     Document Type: Article

References (39)

1. Rupp A, Keith SJ. The costs of schizophrenia. Psychiatr Clin N Am 1993, 16:413-423.
2. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M. Symptoms of schizophrenia: methods, meanings and mechanisms. Arch Gen Psychiatry 1995, 52:341-351. 10.1001/archpsyc.1995.03950170015003, 7726714.
3. Stover EL, Brady L, Marder SR. New paradigms for treatment development. Schizophr Bull 2007, 33:1093-1099. 10.1093/schbul/sbm085, 2632353, 17673495.
4. May PRA. Treatment of schizophrenia 1968, New York: Science House.
5. Rosenheck RA, Leslie D, Keefe R, McEvoy J, Swartz M, Perkins D, Stroup S, Hsaio J, Lieberman J. Barriers to employment for people with schizophrenia. Am J Psychiatr 2006, 163:411-417. 10.1176/appi.ajp.163.3.411, 16513861.
6. Rosenheck RA, Perlick D, Bingham S, Liu-Mares, Collins J, Warren S, Leslie D. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. JAMA 2003, 290:2693-2702. 10.1001/jama.290.20.2693, 14645311.
7. Essock SM, Frisman LK, Covell NH, Hargreaves W. Cost-effectiveness of clozapine compared with conventional antipsychotic medications for patients in state hospitals. Arch Gen Psychiatry 2000, 57:987-994. 10.1001/archpsyc.57.10.987, 11015817.
8. Rosenheck RA, Cramer J, Xu W, Thomas J, Henderson W, Frisman LK, Fye C, Charney D. A comparison of clozapine and haloperidol in the treatment of hospitalized patients with refractory schizophrenia. N Engl J Med 1997, 337:809-815. 10.1056/NEJM199709183371202, 9295240.
9. Brunton LL, Parker KL. Goodman & Gilman's manual of pharmacology and therapeutics 2008, New York: McGraw Hill.
10. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934. 10.1016/j.cell.2010.02.016, 2873093, 20303880.
11. Dean OM, Data-Franco J, Giorlando F, Berk M. Minocycline: therapeutic potential in psychiatry. CNS Drugs 2012, 26:391-401. 10.2165/11632000-000000000-00000, 22486246.
12. Zhang L, Shirayama Y, Iyo M, Hashimoto K. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 2007, 32:2004-2010. 10.1038/sj.npp.1301313, 17228338.
13. Levkovitz Y, Levi U, Braw Y, Cohen H. Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res 2007, 1154:154-162.
14. Plane JM, Shen Y, Pleasure DE, Deng W. Prospects for minocycline neuroprotection. Arch Neurol 2010, 67:1442-1448. 10.1001/archneurol.2010.191, 3127230, 20697034.
15. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol 2008, 31:287-292. 10.1097/WNF.0b013e3181593d45, 18836347.
16. Won SJ, Kim JH, Yoo BH, Sohn M, Kauppinen TM, Park M, Kwon H, Liu J, Suh SW. Prevention of hypoglycemia-induced neuronal death by minocycline. J Neuroinflammation 2012, 9:225. 10.1186/1742-2094-9-225, 3511289, 22998689.
17. Jordan J, Fernandez-Gomez FJ, Ramos M, Ikuta I, Aguirre N, Galind MF. Minocycline and cytoprotection: sheddidng new light on a shadowy controversy. Curr Drug Deliv 2007, 4:225-231. 10.2174/156720107781023938, 17627496.
18. Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W. Minocycline as a neuroprotective agent. Neuroscientist 2005, 11:308-322. 10.1177/1073858405275175, 16061518.
19. Wells JE, Hurlbert RJ, Fehlings MG, Yong VW. Neuroprotection by minocycline facilitates signicant recovery from spinal cord injury in mice. Brain 2003, 126:1628-1637. 10.1093/brain/awg178, 12805103.
20. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:304-307. 10.1016/j.pnpbp.2006.08.013, 17030375.
21. Chaves C, Marque CR, Chaudhry IB, Hussain N, Minhas FA, Oliveria JP. Short-term improvement by minocycline added to olanzapine antipsychotic treatment in paranoid schizophrenia. Schizophr Bull 2009, 35:354.
22. Miyaoka T. Clinical potential of minocycline for schizophrenia. CNS Neurol Disord Drug Targets 2008, 7:376-381. 10.2174/187152708786441858, 18991666.
23. Chaudhry IB, Hussain N, Hallak J, Minhas FA, Dursun SM, Richardson P. Preventing clinical deterioration in first episode psychosis: potential role of minocycline in neruoprotection. Biol Psychiatry 2009, 64:915.
24. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I, Kron S. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010, 71:138-149. 10.4088/JCP.08m04666yel, 19895780.
25. Fekadu A, Desta M, Alem A, Prince M. A descriptive analysis of admissions to amanuel psychiatric hospital in Ethiopia. Ethiop J Health Dev 2007, 21:173-178.
26. Alem A, Kebede D, Fekadu A, Shibre T, Fekadu D, Beyero T, Medhin G, Negash A, Kullgren G. Clinical course and outcome of schizophrenia in a predominantly treatment naïve cohort in Ethiopia. Schizophr Bull 2009, 35:646-654. 10.1093/schbul/sbn029, 2669573, 18448478.
27. Fekadu A, Kebede D, Alem A, Fekadu D, Mogga S, Negash A, Medhin G, Beyero T, Shibre T. Clinical outcome in bipolar disorder in a community-based follow-up study in Butajira-Ethiopia. Acta Psychiatr Scand 2006, 114:426-434. 10.1111/j.1600-0447.2006.00825.x, 17087791.
28. Kebede D, Alem A, Shibre T, Negash A, Fekadu A, Fekadu D, Deyassa N, Jacobsson L, Kullgren G. Onset and clinical course of schizophrenia in Butajira-Ethiopia-a community-based study. Soc Psychiatry Psychiatr Epidemiol 2003, 38:625-631. 10.1007/s00127-003-0678-4, 14614550.
29. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, Washington, DC: American Psychiatric Association, 4, American Psychiatric Association.
30. Leucht S, Kane JM, Kissing W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophr Res 2005, 79:231-238. 10.1016/j.schres.2005.04.008, 15982856.
31. Shibre T, Alem A, Abdulahi A, Araya M, Beyero T, Medhin G, Deyassa N, Negash A, Fekadu A. Trimethoprim as adjuvant treatment in schizophrenia: a double-blind, randomized placebo-controlled clinical trial. Schizophr Bull 2010, 36:846-851. 10.1093/schbul/sbn191, 2894598, 19193743.
32. McGuffin P, Farmer AE, Harvey I. A Polydiagnostic application of operational criteria in studies of psychotic Illness: development and reliability of the OPCRIT System. Arch Gen Psychiatry 1991, 48:764-770. 10.1001/archpsyc.1991.01810320088015, 1883262.
33. World Health Organization Schedules for clinical assessment in neuropsychiatry. Version 2.1 1997, Geneva: WHO, World Health Organization.
34. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276. 10.1093/schbul/13.2.261, 3616518.
35. Kay SR, Opler LA, Fiszbein A. Significance of positive and negative syndromes in chronic schizophrenia. Br J Psychiatry 1986, 149:439-448. 10.1192/bjp.149.4.439, 3814927.
36. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenia. Psychiatry Res 1988, 23:99-110. 10.1016/0165-1781(88)90038-8, 3363019.
37. Mortimer AM. Symptom rating scale and outcome in schizophrenia. Br J Psychiatry 2007, 191:7-14.
38. Sajatovic M, Ramirez LF. Rating scales in mental health 2006, Hudson (Cleveland): Lexi-Comp, 2.
39. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatr 2005, 162:441-449. 10.1176/appi.ajp.162.3.441, 15741458.